등록특허공보(B1) (24) 등록일자 2019년03월28일
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
![Pembrolizumab with Pemetrexed and Platinum Chemotherapy for Untreated Metastatic Non-Squamous Non-Small-Cell Lung Cancer [ID1173]](https://docslib.b-cdn.net/cover/1553/pembrolizumab-with-pemetrexed-and-platinum-chemotherapy-for-untreated-metastatic-non-squamous-non-small-cell-lung-cancer-id1173-61553.webp)
Pembrolizumab with Pemetrexed and Platinum Chemotherapy for Untreated Metastatic Non-Squamous Non-Small-Cell Lung Cancer [ID1173]
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer [ID1173] A Single Technology Appraisal Produced by Peninsula Technology Assessment Group (PenTAG) University of Exeter Medical School, South Cloisters, St Luke’s Campus, Heavitree Road, Exeter EX1 2LU Authors Mr Ed Griffin, Research Fellow1 Dr Caroline Farmer, Research Fellow1 Mr David Packman, Postdoctoral Research Associate 1 Dr Elham Nikram, Postdoctoral Research Associate 1 Mr Justin Matthews, Research Fellow 2 Dr Max Barnish, Postdoctoral Research Associate1 Mr Simon Briscoe, Information Specialist1 Dr Nicole Dorey, Consultant Clinical Oncologist3 Dr Adam Dangoor, Consultant Medical Oncologist4 Dr Ruben Mujica Mota, Senior Lecturer1 1 Peninsula Technology Assessment Group (PenTAG), Exeter, UK 2 Health Statistics, PenCLAHRC, University of Exeter Medical School, Exeter, UK 3 Royal Devon and Exeter NHS Foundation Trust, Exeter, UK 4 University Hospitals Bristol NHS Foundation Trust, Bristol, UK Correspondence to E A Griffin, PenTAG, South Cloisters, St Luke's Campus, Heavitree Road, Exeter EX1 2LU. [email protected] 1 Copyright 2018 Queen's Printer and Controller of HMSO. All rights reserved. Date completed 11/09/2018 Source of funding This report was commissioned by the NIHR Systematic Reviews Programme as project number 17/46/14. JM was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula (NIHR CLAHRC South West Peninsula). Declared competing Dr Nicole Dorey has received educational grants from Amgen, interests of the authors Boehringer Ingelheim, Lilley, Roche, and Teva. Dr Adam Dangoor has received honoraria from Roche and Amgen. -
Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA -
Cisplatin-Resistant Prostate Cancer Model: Differences in Antioxidant System, Apoptosis and Cell Cycle
INTERNATIONAL JOURNAL OF ONCOLOGY 44: 923-933, 2014 Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle JAROMIR GUMULEC1,4, JAN BALVAN1, MARKETA SZTALMACHOVA1,2, MARTINA RAU�ENSKA1,4, VERONIKA �VORAKOVA1, LUCIA KNOPFOVA3, HANA POLANSKA1, KRISTYNA HU�COVA1, BRANISLAV RUTTKAY-NE�ECKY2,4, PETR BABULA5, VOJTECH A�AM2,4, RENE KIZEK2,4, MARIE STIBOROVA6 ��� MICHAL MASARIK1,4 1���������� �� P����l�g���l P�����l�g�, F��ul�� �� M�������, M�����k U��v������, CZ-625 00 B���; 2���������� �� C�������� ��� B�����������, M����l U��v������ �� B���, CZ-613 00 B���; 3���������� �� E����������l B��l�g�, F��ul�� �� S������, M�����k U��v������, CZ-625 00 B���; 4C�����l Eu������ I�����u�� �� T�����l�g�, B��� U��v������ �� T�����l�g�, CZ-616 00 B���; 5���������� �� N��u��l ��ug�, F��ul�� �� P�������, U��v������ �� V��������� ��� P�������u����l S�������, CZ-612 42 B���; 6���������� �� B�����������, F��ul�� �� S������, C���l�� U��v������, CZ-128 40 P��gu� 2, Cz��� R��ubl�� Received Septemb�� 24, 2013; Accepted N�vemb�� 11, 2013 �OI: 10.3892/�j�.2013.2223 Abstract. �����������Differences in�� the��� antioxidant����������� system������, ���������apoptotic ����mech- findings, together with significantly elevated MT, decreased p53 anism and in cell cycl� between prostatic cell lines coul� partiall� and Bax indicate PC-3 to b� cisplatin-resistant. The differences �lucidate the dev�lopment of cisplatin resistance. The aim of this in the antioxidant system and apoptotic mechanisms in PC-3 study was to identify the most characteristic parameter for � cell� may �lucidate the dev�lopment of cisplatin resistance and particular cell line and/or � particular cisplatin treatment using indicate that this cell line may b� �urther studied as � model of � general regression model and to assess whether it is possibl� cytostatic resistance. -
Universidad Autónoma De Nuevo León Facultad De Ciencias Biológicas
UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN FACULTAD DE CIENCIAS BIOLÓGICAS “EVALUACIÓN DE LA ACTIVIDAD ANTICÁNCER DE Thevetia peruviana” POR JOSÉ ALBERTO RAMOS SILVA COMO REQUISITO PARCIAL PARA OBTENER EL GRADO DE DOCTOR EN CIENCIAS CON ORIENTACIÓN EN BIOTECNOLOGÍA JULIO, 2018 UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN FACULTAD DE CIENCIAS BIOLÓGICAS INSTITUTO DE BIOTECNOLOGÍA “Evaluación de la actividad anticáncer de Thevetia peruviana” Por José Alberto Ramos Silva Como requisito parcial para obtener el grado de Doctor en Ciencias con Orientación en Biotecnología Julio, 2018 “Evaluación de la actividad anticáncer de Thevetia peruviana”. Comité de tesis ___________________________________________________________ Presidente: Dr. Hamlet Avilés Arnaut ___________________________________________________________ Secretaria: Dra. Susana de la Torre Zavala ___________________________________________________________ Vocal 1: Dra. Katiushka Arévalo Niño ___________________________________________________________ Vocal 2: Dr. Benito Pereyra Alférez ___________________________________________________________ Vocal 3: Dra. Aida Rodríguez García I “Evaluación de la actividad anticáncer de Thevetia peruviana” Dirección de tesis ___________________________________________________________ Director: Dr. Hamlet Avilés Arnaut II AGRADECIMIENTOS Agradezco al Dr. Hamlet Avilés Arnaut por permite formar parte de su equipo de investigación, así como, por su apoyo, consejo y asesoría por lo cual fue posible llevar acabo este trabajo de investigación. A mis compañeros en general del laboratorio 9 del instituto de biotecnología por todo el apoyo que me han dado y el agradable ambiente de trabajo que se tiene en el laboratorio. A Cristal por ayudarme y enseñarme a iniciar mis experimentos en células. A Faviola por aconsejarme mucho acerca del doctorado y la vida como investigador, ayudarme con múltiples experimentos y la escritura del artículo. A la Dra. Mariana Elizondo y a Álvaro Colin del departamento de microbiología de la Facultad de Medicina por permitirnos utilizar su microscopio de fluorescencia. -
Wednesday, July 10, 2019 4:00Pm
Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital -
Cisplatin Induced Hearing Loss in Paediatric Malignancies
CISPLATIN INDUCED HEARING LOSS IN PAEDIATRIC MALIGNANCIES 1 CISPLATIN INDUCED HEARING LOSS IN PAEDIATRIC MALIGNANCIES A DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF M.S BRANCH IV OTORHINOLARYNGOLOGY EXAMINATION OF THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY TO BE HELD IN APRIL 2016 2 DEPARTMENT OF OTORHINOLARYNGOLOGY CHRISTIAN MEDICAL COLLEGE VELLORE DECLARATION I declare that this dissertation entitled “Cisplatin induced hearing loss in Paediatric malignancies’’ submitted towards fulfilment of the requirements of the Tamil Nadu Dr. M.G.R. Medical University for the MS Branch IV, Otorhinolaryngology examination to be conducted in April 2016, is the bonafide work of Dr. Susana Mathew, postgraduate student in the Department of Otorhinolaryngology, Christian Medical College, Vellore Dr. Susana Mathew Postgraduate Student (M S Otorhinolaryngology ) Register Number: 221314355 Department of Otorhinolaryngology Christian Medical College Vellore. 3 DEPARTMENT OF OTORHINOLARYNGOLOGY CHRISTIAN MEDICAL COLLEGE VELLORE CERTIFICATE This is to certify that the dissertation entitled “Cisplatin induced hearing loss in paediatric malignancies’’ is a bonafide original work of Dr. Susana Mathew, submitted in partial fulfilment of the rules and regulations for the M S Branch IV, Otorhinolaryngology examination of The Tamil Nadu Dr. M.G.R. Medical University to be held in April 2016. Principal Head Of Department Dr. Alfred Job Daniel Dr. John Mathew Christian Medical College Professor and Head, Vellore- 632002 Department of Otorhinolaryngology, India. Christian Medical College, Vellore. 4 DEPARTMENT OF OTORHINOLARYNGOLOGY CHRISTIAN MEDICAL COLLEGE VELLORE CERTIFICATE This is to certify that the dissertation entitled “Cisplatin induced hearing loss in paediatric malignancies’’ is a bonafide original work of Dr. Susana Mathew, submitted in partial fulfilment of the rules and regulations for the M S Branch IV, Otorhinolaryngology examination of The Tamil Nadu Dr. -
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG . -
Exploration of the Medical Periodic Table: Towards New Targets Nicolas P
Electronic Supplementary Material (ESI) for Chemical Communications This journal is © The Royal Society of Chemistry 2013 Exploration of the medical periodic table: towards new targets Nicolas P. E. Barry and Peter J. Sadler* Supporting Information Table S1. Some examples of uses of the elements in therapy and diagnosis. These entries have guided our colour-coding in Fig.1, which is illustrative only and not comprehensive. Z Symbol Element Some medically-relevant uses Essential element; pH tightly controlled but variable: blood ~7.4, lysomes 4–5, tumour tissue 6–7, 1 H Hydrogen endosomes (transferrin) 5.5; duodenum 6–6.5, large intestine 5.5–7, stomach 1–3; 2H for kinetic control of organic drugs; 3H as radiotracer. He-O ; for treatment of chronic obstructive 2 He Helium 2 pulmonary disease; hyperpolarised 3He for MRI. 3 Li Lithium Li2CO3: drug for treatment of bipolar disorders. Compounds can provoke severe immune response 4 Be Beryllium (chronic beryllium disease). Boromycin: bacteriocidal polyether-macrolide antibiotic. Boronophenylalanine-based Boron 5 B Boron Neutron Capture Therapy in combination with Cetuximab in clinical Phase I trials for head and neck cancer treatments. Essential element; body produces 3-6 mL CO per 6 C Carbon day- suppresses organ rejection, ‘neurotransmitter’; 11C, 14C used in radiopharmaceuticals. Essential element; NO is a muscle relaxant, 7 N Nitrogen vasodilator, hypotensive, ‘neurotransmitter’; 13N used in radiopharmaceuticals. Essential element; Reactive oxygen species (ROS), 8 O Oxygen 1 - - e.g. O2, O2 , H2O2, O3, ONO2 . Essential element; Toughens tooth enamel as 9 F Fluorine component of (fluoro)apatite; 18F labelling, positron emission, radioimaging, PET scans. -
JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
JULY 2019 MRx Pipeline A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Michelle Booth, Pharm D Director, Medical Pharmacy Strategy Becky Borgert, PharmD, BCOP Pipeline Drug List Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Drug Information Pharmacist Glossary Robert Greer, RPh, BCOP Senior Director, Clinical Strategy and Programs YuQian Liu, PharmD Manager, Specialty Clinical Programs Troy Phelps Senior Director, Analytics Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Magellan Rx Management. 1 | magellanrx.com INTRODUCTION Welcome to the MRx Pipeline. In its third year of publication, this quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report. -
Efficacy and Safety of Topical Sofpironium Bromide Gel for the Treatment of Axillary Hyperhidrosis: a Phase II, Randomized, Controlled, Double-Blinded Trial
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial Brandon Kirsch, MD,a Stacy Smith, MD,b Joel Cohen, MD,c,d Janet DuBois, MD,e Lawrence Green, MD,f Leslie Baumann, MD,g Neal Bhatia, MD,h David Pariser, MD,i Ping-Yu Liu, PhD,j Deepak Chadha, MS, MBA,a and Patricia Walker, MD, PhDa BoulderandGreenwoodVillage,Colorado;Miami,Florida;Encinitas,Irvine,andSanDiego,California; Austin, Texas; Washington, DC; Norfolk, Virginia; Seattle, Washington Background: Primary axillary hyperhidrosis has limited noninvasive, effective, and well-tolerated treatment options. Objective: To evaluate the topical treatment of axillary hyperhidrosis with the novel anticholinergic sofpironium bromide. Methods: A phase II, multicenter, randomized, controlled, double-blinded study. Participants were randomized to 1 of 3 dosages or vehicle, with daily treatment for 42 days. Coprimary end points were the percentage of participants exhibiting $1-point improvement in the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) score by logistic regression, and change in HDSM-Ax as a continuous measure by analysis of covariance. Pair-wise comparisons were 1-sided with a = 0.10. Results: At the end of therapy, 70%, 79%, 76%, and 54% of participants in the 5%, 10%, 15%, and vehicle groups exhibited $1-point improvement in HDSM-Ax (P \.05). Least-square mean (SE) changes in HDSM- Ax were À2.02 (0.14), À2.09 (0.14), 2.10 (0.14), and À1.30 (0.14) (all P # .0001). Most treatment-related adverse events were mild or moderate. Limitations: Not powered to detect changes in gravimetric sweat production. -
West Virginia Resident Is First American To
CLINICAL ONCOLOGY AND RESEARCH | ISSN 2613-4942 Available online at www.sciencerepository.org Science Repository Case Report West Virginia Resident is First American to Receive Dicycloplatin Chemotherapy: A WVU Urologic Oncology Case Report Mohamad Salkini1, Chad Morley1, Chad Crigger1, Shunchang Jiao2 and Jing Jie Yu3* 1Department of Urology, School of Medicine, WVU, Morgantown, WV, U.S.A 2Oncology Department of Internal Medicine, PLA Hospital, Beijing, China 3WVU Cancer Institute, School of Medicine, and School of Pharmacy, West Virginia University, Morgantown, WV, U.S.A A R T I C L E I N F O A B S T R A C T Article history: A 65-year-old Caucasian male presented with increasing hematuria over four months in 2016. Work up and Received 24 June, 2018 scans revealed a 1.5 cm bladder mass, with a subsequent pathologic diagnosis of non-invasive high-grade Accepted 6 July, 2018 papillary urothelial carcinoma. The patient declined BCG Immunotherapy and traveled to China soon after Published 16 July 2018 diagnosis and transurethral resection for Dicycloplatin (DCP) chemotherapy. DCP is approved by the Keywords: Chinese FDA but only available at present in military hospitals. It is similar in molecular structure to Platinum Chemotherapy platinum-based chemotherapy drugs used in the West, its side effects reported to be more tolerable. The Dicycloplatin patient received 8 weeks of IV DCP chemotherapy – he only experienced mild nausea, myralgia, a relative Tolerable Side Effects leukopenia and thrombocytopenia (though within normal limits) and, importantly, no alopecia – then Bladder Cancer returned to WV for quarterly surveillance. No recurrence of tumor has been observed to date; the most recent cystoscopy was on April 24, 2018, 22 months after diagnosis and resection. -
Review Article Toxicity Comparisons of Eight Chemotherapy Regimens in the Treatment of Metastatic/Advanced Non-Small-Cell Lung Cancer: a Network Meta-Analysis
Int J Clin Exp Med 2017;10(6):8709-8719 www.ijcem.com /ISSN:1940-5901/IJCEM0053945 Review Article Toxicity comparisons of eight chemotherapy regimens in the treatment of metastatic/advanced non-small-cell lung cancer: a network meta-analysis Ziming Cheng, Shizhen Hou, Yi Sun, Yubing Wu, Bing Liu, Maoxi Yuan, Xiangdong Wang Department of Thoracic Surgery, Central Hospital of Linyi, Linyi 276400, P. R. China Received March 27, 2017; Accepted May 10, 2017; Epub June 15, 2017; Published June 30, 2017 Abstract: To compare the toxicity of different first-line chemotherapy regimens in the treatment of stage III/IV non-small-cell lung cancer (NSCLC) by network meta-analysis. The PubMed, Cochrane Library and EMBASE were searched. Randomized controlled trials (RCTs) concerning different first-line chemotherapy regimens for stage III/IV NSCLC from the day of databases establishment to August, 2016 were included into the study. Direct and indirect comparisons were combined by using network meta-analysis to evaluate the combined odds ratio (OR) and draw the surface under the cumulative ranking (SUCRA) curve of toxicity of different first-line chemotherapy regimens. A total of 12 qualified RCTs about ten first-line chemotherapy regimens (Gemcitabine, Cisplatin + Gemcitabine, Pa- clitaxel + Gemcitabine, Carboplatin + Gemcitabine, Carboplatin + Paclitaxel, Vinorelbine + Gemcitabine, Cisplatin + Gemcitabine + Vinorelbine, Vinorelbine + Carboplatin, Docetaxel + Gemcitabine, Dicycloplatin + Paclitaxel) were included into the study. According to network meta-analysis, the hematologic toxicity of Gemcitabine, Paclitaxel + Gemcitabine and Docetaxel + Gemcitabine regimens was lower, while that of Carboplatin + Paclitaxel and Cisplatin + Gemcitabine + Vinorelbine regimens was higher. The incidence of hematologic toxicity of Paclitaxel + Gemcitabine and Docetaxel + Gemcitabine regimens was lower, while Carboplatin + Paclitaxel and Cisplatin + Gemcitabine + Vinorelbine regimens had higher incidence of hematologic toxicity.